MedPath

Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.

Not Applicable
Completed
Conditions
Injections, Intradermal
Interventions
Device: ID adapter (autodisable)
Device: ID adapter (side load)
Registration Number
NCT01943110
Lead Sponsor
PATH
Brief Summary

The purpose of this study is to evaluate whether two intradermal (ID) vaccine delivery devices can safely and precisely inject liquid into the intradermal layer of the skin in three different injection locations

Detailed Description

This study is a preliminary device safety and performance evaluation in healthy adult volunteers (ages 18-55 years).

Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:

* Upper deltoid with the side-load ID adapter

* Upper deltoid with the autodisable (AD) ID adapter

* Suprascapular (behind the shoulder) with the side-load ID adapter

* Suprascapular with the AD ID adapter

* Forearm with the side-load ID adapter

* Forearm with the AD ID adapter

Intradermal administration of each injection will be assessed:

* The liquid remaining on the surface of the skin will be blotted with absorbent paper and the amount of liquid present will be recorded.

* The formation of an intradermal wheal will be observed, and the diameter of the wheal measured using a ruler or similar measurement tool.

* A photo of the injection site will be taken.

Injections will be assessed for safety by observation of injection sites for any local adverse events.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Female and male participants ages 18 to 55 years.
  • Healthy enough to participate in the clinical trial per site investigator assessment.
  • Healthy skin on the upper deltoid, suprascapular, and forearm regions (both sides of the body).
  • Able to provide signed informed consent and understand study procedures per ICH/GCP guidelines.
  • Literate in English.
  • Available by telephone 48 hours after the study visit.
Exclusion Criteria
  • Skin abnormalities on upper deltoid, suprascapular, and forearm regions of either side of the body (scars, rash, infection), tattoo at the injection site, or other skin conditions that would interfere with the ability to visualize an intradermal injection in the opinion of the investigator.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Saline injection with ID adaptersID adapter (autodisable)Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin: * Upper deltoid with the side-load ID adapter * Upper deltoid with the AD ID adapter * Suprascapular (behind the shoulder) with the side-load ID adapter * Suprascapular with the AD ID adapter * Forearm with the side-load ID adapter * Forearm with the AD ID adapter
Saline injection with ID adaptersID adapter (side load)Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin: * Upper deltoid with the side-load ID adapter * Upper deltoid with the AD ID adapter * Suprascapular (behind the shoulder) with the side-load ID adapter * Suprascapular with the AD ID adapter * Forearm with the side-load ID adapter * Forearm with the AD ID adapter
Primary Outcome Measures
NameTimeMethod
Proportion of Injections Delivered to the Intradermal Layer of the Skin1 day

The proportion of saline injections resulting in delivery to the intradermal layer of the skin will be assessed by measurement of intradermal wheals with diameters ≥ 5mm and the volume of liquid injected.

Secondary Outcome Measures
NameTimeMethod
Proportion of Injections With Safety EventsWithin 30 minutes and within 48 hours of injection

The proportion of injections with safety events will be calculated for events occurring within 30 minutes and within 48 hours of injection.

Trial Locations

Locations (1)

Rainier Clinical Research Center

🇺🇸

Renton, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath